Kwan Soo Byun Selected Research

Lamivudine (Epivir)

12/2017	Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
1/2017	Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study.
11/2014	Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
1/2013	Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
4/2012	Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.
12/2011	Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients.
6/2010	Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B.
7/2009	Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.
7/2008	Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
1/2008	Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kwan Soo Byun Research Topics

Disease

40	Chronic Hepatitis B 01/2024 - 12/2002
24	Hepatocellular Carcinoma (Hepatoma) 01/2024 - 08/2002
23	Fibrosis (Cirrhosis) 01/2024 - 10/2007
17	Liver Cirrhosis (Hepatic Cirrhosis) 01/2023 - 09/2003
12	Neoplasms (Cancer) 03/2021 - 01/2005
10	Infections 01/2023 - 12/2003
7	Chronic Hepatitis C 01/2023 - 12/2004
6	Non-alcoholic Fatty Liver Disease 04/2022 - 07/2004
6	Hepatitis B 01/2022 - 01/2008
6	End Stage Liver Disease 01/2021 - 08/2007
5	Liver Diseases (Liver Disease) 01/2023 - 09/2003
5	Disease Progression 01/2017 - 12/2002
5	Hemorrhage 12/2016 - 10/2007
4	Acute Kidney Injury (Acute Renal Failure) 05/2020 - 11/2013
4	Hepatitis 01/2014 - 03/2008
3	Ascites 01/2024 - 11/2009
3	Neoplasm Metastasis (Metastasis) 03/2021 - 06/2002
3	Inflammation (Inflammations) 01/2021 - 12/2015
3	Esophageal and Gastric Varices (Esophageal Varices) 12/2016 - 08/2010
3	Gallstones (Gallstone) 06/2010 - 10/2003
2	Thrombosis (Thrombus) 03/2021 - 12/2017
2	Brain Diseases (Brain Disorder) 05/2020 - 02/2018
2	Hepatic Encephalopathy 02/2018 - 01/2014
2	Neoplasms, Cystic, Mucinous, and Serous 02/2017 - 01/2006
2	Varicose Veins (Varicose Vein) 12/2016 - 01/2016
2	Viremia 11/2014 - 12/2009
2	Pyloric Stenosis 07/2013 - 06/2011
2	Pathologic Constriction (Stenosis) 07/2013 - 06/2011
2	Pain (Aches) 06/2012 - 06/2002
2	Nausea 06/2012 - 03/2008
2	Lymphatic Metastasis 04/2012 - 03/2007
1	Alcoholism (Alcohol Abuse) 01/2024
1	Hepatitis C 01/2023
1	Body Weight (Weight, Body) 01/2022

Drug/Important Bio-Agent (IBA)

25	Antiviral Agents (Antivirals)IBA 01/2024 - 12/2003
15	entecavir FDA Link 01/2022 - 01/2009
15	Hepatitis B e AntigensIBA 12/2017 - 12/2002
14	Lamivudine (Epivir)FDA Link 12/2017 - 12/2002
9	Tenofovir (Viread)FDA Link 01/2022 - 07/2008
9	adefovirIBA 01/2019 - 08/2007
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2014
7	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2017 - 09/2007
7	clevudineIBA 07/2014 - 05/2006
6	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 03/2011
4	Alanine Transaminase (SGPT)IBA 11/2022 - 03/2011
4	CholesterolIBA 01/2022 - 10/2003
4	Sorafenib (BAY 43-9006)FDA Link 03/2021 - 03/2014
4	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2017
4	BilirubinIBA 01/2021 - 06/2002
4	Ribavirin (Virazole)FDA LinkGeneric 03/2013 - 12/2004
3	tenofovir alafenamideIBA 01/2024 - 01/2022
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 07/2021 - 04/2019
3	InterferonsIBA 06/2021 - 09/2007
3	Indicators and Reagents (Reagents)IBA 01/2020 - 09/2016
3	SodiumIBA 02/2018 - 08/2007
3	AntigensIBA 09/2016 - 03/2011
3	Fatty Acids (Saturated Fatty Acids)IBA 12/2015 - 07/2004
3	Cytidine Triphosphate (CTP)IBA 04/2012 - 08/2007
3	Matrix Metalloproteinases (MMPs)IBA 03/2007 - 09/2003
2	Glycoproteins (Glycoprotein)IBA 01/2023 - 03/2014
2	Simvastatin (Zocor)FDA LinkGeneric 01/2022 - 06/2014
2	N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamideIBA 01/2022 - 06/2014
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2022 - 06/2014
2	Tumor Biomarkers (Tumor Markers)IBA 07/2021 - 03/2014
2	Proteins (Proteins, Gene)FDA Link 07/2021 - 01/2020
2	Cystatin CIBA 01/2019 - 11/2009
2	CreatinineIBA 01/2019 - 11/2009
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2015 - 01/2008
2	acarboxyprothrombin (PIVKA)IBA 03/2015 - 03/2014
2	Interferon-alpha (Interferon Alfa)IBA 01/2015 - 12/2004
2	EnzymesIBA 03/2014 - 01/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2012 - 03/2009
2	adefovir dipivoxil (Hepsera)FDA Link 09/2010 - 08/2007
2	PPAR alphaIBA 01/2008 - 07/2004
2	Viral DNAIBA 12/2006 - 12/2003
2	ErbB Receptors (EGF Receptor)IBA 01/2005 - 10/2003
1	FumaratesIBA 01/2024
1	((1- ((2- amino- 9H- purin- 9- yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxylIBA 01/2024
1	maleic acid (maleate)IBA 01/2024
1	SofosbuvirIBA 01/2023
1	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2023
1	velpatasvirIBA 01/2023
1	Ethanol (Ethyl Alcohol)IBA 11/2022
1	Thioacetamide (Thioacetamid)IBA 01/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022
1	Drinking WaterIBA 01/2022
1	CollagenIBA 01/2022
1	HDL CholesterolIBA 01/2022
1	lentil lectinIBA 07/2021
1	Factor VIII (Coagulation Factor VIII)IBA 07/2021
1	Epidermal Growth Factor (EGF)IBA 07/2021

Therapy/Procedure

33	Therapeutics 11/2022 - 08/2002
4	Liver Transplantation 10/2022 - 03/2010
3	Drug Therapy (Chemotherapy) 03/2021 - 08/2002
3	Stents 07/2013 - 07/2006
2	Aftercare (After-Treatment) 01/2021 - 04/2012
2	Ligation 12/2016 - 01/2016
2	Sclerotherapy 12/2016 - 01/2016
2	Self Expandable Metallic Stents 07/2013 - 06/2011
2	Gastrectomy 04/2012 - 06/2011